Education
About Us
Working with TipRanks
Follow Us
Sanofi SA (SNY)
:SNY
Earnings Data
Report Date
Jan 29, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.83Last Year’s EPS
0.68Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Sanofi demonstrated strong growth in Q3 driven by record-breaking sales, particularly from Dupixent and new product launches, along with significant advancements in vaccine innovation. However, there were challenges in vaccine sales due to competitive pressures and program discontinuations, as well as impacts from foreign exchange rates.Company Guidance
Record-Breaking Sales and Growth
Q3 2025 sales reached EUR 12.4 billion, up 7% year-over-year. Dupixent achieved EUR 4 billion in quarterly sales for the first time, contributing significantly to growth.
Strong Performance of New Launches
New product launches delivered EUR 1.8 billion in Q3, growing over 40% and representing 15% of total sales.
Dupixent's Milestone and Expansion
Dupixent sales surpassed EUR 4 billion in the quarter, with a 30% increase in patient numbers over the last 12 months. Sales outside the U.S. grew by 21%, exceeding EUR 1 billion.
Vaccine Business and Innovation in Flu Vaccines
Sanofi's high-dose flu vaccine, Efluelda, showed a 32% reduction in flu hospitalizations compared to standard dose vaccines, expanding access.
Financial Performance and Margin Improvement
Net sales grew by 7% at constant exchange rates, and business gross margin increased by 2.3 percentage points with continued improvement in product mix.
Commitment to Global Health
Sanofi's global health unit treated 1 million patients for noncommunicable diseases in over 40 countries since 2021, with plans to reach 2 million by 2030.
SNY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SNY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 24, 2025 | $49.52 | $51.64 | +4.28% |
Jul 31, 2025 | $49.25 | $45.64 | -7.33% |
Apr 24, 2025 | $51.38 | $51.89 | +0.99% |
Jan 30, 2025 | $50.54 | $52.48 | +3.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Sanofi SA (SNY) report earnings?
Sanofi SA (SNY) is schdueled to report earning on Jan 29, 2026, Before Open (Confirmed).
What is Sanofi SA (SNY) earnings time?
Sanofi SA (SNY) earnings time is at Jan 29, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SNY EPS forecast?
SNY EPS forecast for the fiscal quarter 2025 (Q4) is 0.83.
